Potential of prescription registries to capture individual-level use of aspirin and other nonsteroidal anti-inflammatory drugs in Denmark: Trends in utilization 1999-2012

Clinical Epidemiology

Volumn 6, Issue 1, 2014, Pages 155-168

  Schmidt, Morten ^a   Hallas, Jesper ^b   Friis, Søren ^a,c  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

Drug utilization; NSAID; Over the counter; Registries

Indexed keywords

ACECLOFENAC; ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2 INHIBITOR; DEXIBUPROFEN; DEXKETOPROFEN; DICLOFENAC; ETODOLAC; FENAMIC ACID DERIVATIVE; FENBUFEN; FENOPROFEN; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; KETOROLAC; LORNOXICAM; MELOXICAM; NABUMETONE; NAPROXEN; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PHENYLBUTAZONE; PIROXICAM; PROPIONIC ACID DERIVATIVE; SULINDAC; TENOXICAM; TOLFENAMIC ACID; TOLMETIN; UNINDEXED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DENMARK; DRUG INDICATION; DRUG MARKETING; DRUG MEGADOSE; DRUG USE; DRUG UTILIZATION; ELDERLY CARE; FEMALE; HUMAN; INFLAMMATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PAIN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRESCRIPTION REGISTRY; PREVALENCE; PRIMARY HEALTH CARE; REGISTER; SEX DIFFERENCE; TREND STUDY;

EID: 84900551630     PISSN: None     EISSN: 11791349     Source Type: Journal    
DOI: 10.2147/CLEP.S59156     Document Type: Article

References (35)

1. Schmidt M, Johansen MB, Lash TL, Christiansen CF, Christensen S, Sørensen HT. Antiplatelet drugs and risk of subarachnoid hemorrhage: a population-based case-control study. J Thromb Haemost. 2010;8(7): 1468-1474.
2. Schmidt M, Christiansen CF, Mehnert F, Rothman KJ, Sørensen HT. Non-steroidal anti-inflammatory drug use and risk of atrial fibrillation or flutter: population based case-control study. BMJ. 2011;343:d3450.
3. Gaist D, García-Rodríguez LA, Sørensen HT, Hallas J, Friis S. Use of low-dose aspirin and non-aspirin nonsteroidal anti-inflammatory drugs and risk of glioma: a case-control study. Br J Cancer. 2013;108(5):1189-1194.
4. Lidegaard Ø. Reply to: Stroke and myocardial infarction with hormonal contraception. N Engl J Med. 2012;367:1264.
5. Caporaso NE. Statins and cancer-related mortality-let's work together. N Engl J Med. 2012;367(19):1848-1850.
6. Dawwas MF. Statin use and reduced cancer-related mortality. Engl J Med. 2013;368(6):574-575.
7. Fosbøl EL, Gislason GH, Jacobsen S, et al. The pattern of use of non-steroidal anti-inflammatory drugs (NSAIDs) from 1997 to 2005: a nationwide study on 4.6 million people. Pharmacoepidemiol Drug Saf. 2008;17(8):822-833.
8. Bresalier RS, Sandler RS, Quan H, et al; Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352(11):1092-1102.
9. Bhala N, Emberson J, Merhi A, et al; Coxib and traditional NSAID Trialists' (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894): 769-779.
10. Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011;342:c7086.
11. Ministry of Health and Prevention. Health Care in Denmark. 2008. Available from: http://www.sum.dk/Aktuelt/Publikationer/~/media/Filer%20-%20Publikationer_i_pdf/2008/UK_Healthcare_in_dk/pdf.ashx. Accessed December 1, 2013.
12. Pedersen CB. The Danish Civil Registration System. Scand J Public Health. 2011;39(Suppl 7):22-25.
13. Johannesdottir SA, Horváth-Puhó E, Ehrenstein V, Schmidt M, Pedersen L, Sørensen HT. Existing data sources for clinical epidemiology: The Danish National Database of Reimbursed Prescriptions. Clin Epidemiol. 2012;4:303-313.
14. Kildemoes HW, Sørensen H, Hallas J. The Danish National Prescription Registry. Scand J Public Health. 2011;39(Suppl 7):38-41.
15. World Health Organization Collaborating Centre for Drug Statistics Methodology. ATC Classification Index with DDDs. World Health Organization Collaborating Centre for Drug Statistics Methodology, Oslo, 2013. Available from: http://www.whocc.no/atc_ddd_index/. Accessed December 1, 2013.
16. Danish Serum Institute. Statistics on the annual sale of medicines in Denmark based on the data from the Register of Medicinal Product Statistics. Available from: http://www.medstat.dk/en. Accessed December 1, 2013.
17. Danish Pharmaceutical Information. Drugs and package sizes on the Danish drug market. Available for search from http://pro.medicin.dk. Accessed December 1, 2013.
18. Danish Health and Medicines Authority. Over-the-counter medicines in Denmark. Available from: http://sundhedsstyrelsen.dk/en/medicines/sale/over-the-counter-medicines. Accessed December 1, 2013.
19. Hawton K, Bergen H, Simkin S, et al. Long term effect of reduced pack sizes of paracetamol on poisoning deaths and liver transplant activity in England and Wales: interrupted time series analyses. BMJ. 2013;346:f403.
20. Danish Health and Medicines Authority. Special warning on the labelling of pain relievers. October 1, 2004. Available from: http://laegemiddelstyrelsen.dk/en/topics/authorisation-and-supervision/licensing-of-medicines/summaries-of-product-characteristics,-pa---labelling/special-warning-on-the-labelling-of-pain-relievers. Accessed December 1, 2013.
21. Danish Health and Medicines Authority. Age limit of 18 years introduced for buying painkillers. March 7, 2011. Available from: http://laegemiddelstyrelsen.dk/en/service-menu/news/age-limit-of-18-years-introduced-for-buy--ainkillers. Accessed December 1, 2013.
22. Danish Health and Medicines Authority. Painkillers to be prescription only in Denmark from September 30, 2013. Available from: http://sundhedsstyrelsen.dk/en/news/2013/painkillers-to-be-prescription-only-in-denmark-from-30-september-2013. Accessed December 1, 2013.
23. Day RO, Graham GG. Non-steroidal anti-inflammatory drugs (NSAIDs). BMJ. 2013;346:f3195.
24. Fuster V, Sweeny JM. Aspirin: a historical and contemporary therapeutic overview. Circulation. 2011;123(7):768-778.
25. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329): 71-86.
26. Anderson JW, Nicolosi RJ, Borzelleca JF. Glucosamine effects in humans: a review of effects on glucose metabolism, side effects, safety considerations and efficacy. Food Chem Toxicol. 2005;43(2):187-201.
27. Capone ML, Tacconelli S, Di Francesco L, Sacchetti A, Sciulli MG, Patrignani P. Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediat. 2007;82(1-4):85-94.
28. Wilcox CM, Cryer B, Triadafilopoulos G. Patterns of use and public perception of over-the-counter pain relievers: focus on nonsteroidal antiinflammatory drugs. J Rheumatol. 2005;32(11):2218-2224.
29. Danish Health and Medicines Authority. New information about cardiovascular adverse reactions from the use of NSAID. Danish Medicines Agency. November 20, 2008. Available from: http://sundhedsstyrelsen.dk/en/news/2008/new-information-about-cardiovascular-adverse-reactions-from-the-use-of-nsaid. Accessed December 1, 2013.
30. Gislason GH, Fosbøl EL, Grande P, et al. Danish Society of Cardiology. Recommendations on NSAID use in patients with cardiovascular disease. 2009. Available from: http://www.cardio.dk/rapporter/holdningspapir-menu. Accessed December 1, 2013.
31. Henry D, Lim LL, Garcia Rodriguez LA, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ. 1996;312(7046):1563-1566.
32. Castellsague J, Riera-Guardia N, Calingaert B, et al; Safety of Non-Steroidal Anti-Inflammatory Drugs (SOS) Project. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012;35(12):1127-1146.
33. van Staa TP, Smeeth L, Persson I, Parkinson J, Leufkens HG. What is the harm-benefit ratio of Cox-2 inhibitors? Int J Epidemiol. 2008;37(2): 405-413.
34. Fosbøl EL, Gislason GH, Jacobsen S, et al. Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther. 2009;85(2):190-197.
35. European Medicines Agency. Assessment report for non-steroidal anti-inflammatory drugs (NSAIDs) and cardiovascular risk. 2012. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Report/2012/11/WC500134717.pdf. Accessed December 1, 2013.